Ropes & Gray advised Xeris Biopharma Holdings in an exclusive worldwide collaboration and license agreement with Beta Bionics for the development and commercialization of a glucagon product using Xeris’ XeriSol technology for use in Beta Bionics’ proprietary bi-hormonal pump and pump systems for people with diabetes. The transaction was announced on May 6.
Under the license agreement, Xeris has the potential to receive development payments, plus low double-digit royalties based on future sales of the Xeris glucagon for pumps and pump systems. Glucagon is a hormone that increases blood sugar level and prevents it from dropping too low.
The Ropes & Gray team was led by life sciences licensing partner Abigail Gregor and life sciences licensing associates Nicole Rohr and Esteban De La Torre.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.